Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes

Diabetic Medicine

Volumn 13, Issue SUPPL. 5, 1996, Pages

  Nauck, M ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Gastric emptying; Glucagon; Glucagon like peptide; Insulin; Type 2 diabetes

Indexed keywords

GENE PRODUCT; GLUCAGON LIKE PEPTIDE 1; INSULIN;

ANOREXIA; CONFERENCE PAPER; GLUCAGON RELEASE; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN SYNTHESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; STOMACH EMPTYING;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GASTRIC EMPTYING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; PEPTIDE FRAGMENTS; POSTPRANDIAL PERIOD; PROTEIN PRECURSORS;

EID: 0029817752     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lopez LC, Frazier ML, Su C-J, Kumar A, Saunders GF. Mammalian pancreatic proglucagon contains three glucagon-related peptides. Proc Natl Acad Sci USA 1983; 80: 5485-5489.
2. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human proglucagon gene. Nature 1983; 304: 368-371.
3. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 1994; 43: 535-539.
4. Ørskov C, Bersani M, Johnsen AH, Højrup P, Holst JJ. Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J Biol Chem 1989; 264: 12826-12829.
5. Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985; 28: 704-707.
6. Ørskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 (proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum and nonantral stomach. Endocrinol 1988; 123: 2009-2013.
7. Kawai K, Suzuki S, Ohashi S, Mukai H, Ohmori H, Murayama Y, et al. Comparison of the effects of glucagon-like peptide-1- (1-37) and - (7-37) and glucagon on islet hormone release from the isolated perfused canine and rat pancreases. Endocrinol 1989; 124: 1768-1773.
8. Weir GC, Mojsov S, Hendrick GK, Habener JF. Glucagon-like peptide I (7-37) actions on endocrine pancreas. Diabetes 1989; 38: 338-342.
9. Kreymann B, Ghatei MA, Williams G, Bloom SR. Glucagon-like peptide 1 7-36: a physiological incretin in man. Lancet 1987; II: 1300-1304.
10. Nauck M, Bartels E, Ørskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76: 912-917.
11. Qualmann C, Nauck MA, Holst JJ, Ørskov C, Creutzfeldt W. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol 1995; 32: 13-16.
12. Nauck MA, Ettler R, Niedereichholz U, Ørskov C, Holst JJ, Schmiegel W. Inhibition of gastric emptying by GLP-1 [7-36 amide] or [7-37]: effects on postprandial glycaemia and insulin secretion man (abstract). Gut 1995; 37: (suppl 2): A124.
13. George JD. New clinical method for measuring the rate of gastric emptying; The double sampling test meal. Gut 1968; 9: 237-242.
14. Hurwitz A. Measuring gastric volume by dilution. Gut 1981; 22: 85-93.
15. Willms B, Werner J, Ørskov C, Holst JJ, Creutzfeldt W, Nauck M. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in Type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327-332.
16. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 [7-36 amide] in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.
17. Weber I, Bach-Esser AK, Bach I, Richter S, Ørskov C, Holst JJ, et al. Prolonged normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in Type 2-diabetic patients (abstract). Diabetologia 1995; 38 (suppl 1): A171.
18. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 (GLP-1) [7-36 amide] but not of synthetic human gastric inhibitory polypeptide (GIP) in patients with Type 2 diabetes mellitus. J Clin Invest 1993; 91: 301-307.
19. Nauck MA, Hornberger E, Siegel EG, Allen RC, Eaton RP, Eben R, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-498.
20. Tillil H, Shapiro ET, Miller MA, Karrison T, Frank BH, Galloway JA, et al. Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans. Am J Physiol (Endocrinol Metab) 1988; 254: E349-E357.
21. Fehmann H-C, Habener JF. Insulinotropic hormone glucagon-like peptide-1 (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 cells. Endocrinol 1992; 130: 159-166.
22. Wettergen A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 87-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-673.
23. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF. Insulinotropic action of glucagon-like peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 1992; 15: 270-276.
24. Gutniak M, Ørskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 [7-36 amide] in normal subjects and patients with diabetes. N Engl J Med 1992; 326: 1316-1322.
25. Dupré J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, et al. Glucagon-like peptide 1 reduces postprandial glycemic excursions in IDDM. Diabetes 1995; 44: 626-630.
26. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72.
27. Valverde I, Villanueva-Petacarillo ML. Target tissues for GLP-1 (7-36 amide). Digestion 1993; 54: 343.
28. Fürnsinn C, Ebner K, Waldhäusl W. Failure of GLP-1 [7-36] amide to affect glycogenesis in rat skeletal muscle. Diabetologia 1995; 38: 864-867.
29. Creutzfeldt W, Kleine N, Willms B, Ørskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycaemia by exogenous glucagon-like peptide 1 [7-36 amide] in Type 1 (insulin-dependent)-diabetic patients. Diabetes Care 1996; in press.
30. Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with Type 2 diabetes mellitus. Castroenterol 1995; 109: 755-765.
31. Ritzel R. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 1995; 38: 720-725.
32. Nauck MA, Wollschläger D, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with Type 2-diabetes (abstract) Diabetologia 1995; 38 (suppl 1): A39.
33. 2-Terminus in Type 2 diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-1131.